| Breast Cancer |
1 |
1 |
| Chemotherapy |
0 |
0.86 |
| Adjuvant Chemotherapy |
0 |
0.66 |
| HER2-Negative Breast Cancer |
0 |
0.99 |
| Cancer |
0 |
0.32 |
| Breast |
0 |
0.25 |
| Genomic Medicine |
0 |
0.24 |
| Endocrine Therapy |
0 |
0.18 |
| Amenorrhea |
0 |
0.11 |
| Selective Estrogen Receptor Modulators |
0 |
0.1 |
| Lymph Node |
0 |
0.07 |
| Sentinel Lymph Node |
0 |
0.06 |
| Aromatase Inhibitors |
0 |
0.05 |
| Epidermal Growth Factor Receptor |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Stigma |
0 |
0.05 |
| Clinical Research |
0 |
0.04 |
| Ovarian Ablation |
0 |
0.04 |
| Adverse Effects |
0 |
0.02 |
| Brain |
0 |
0.02 |
| Burns |
0 |
0.02 |
| Disease Recurrence |
0 |
0.02 |
| Hematology |
0 |
0.02 |
| Neoadjuvant Therapy |
0 |
0.02 |
| Patient Safety |
0 |
0.02 |
| Shared Decision-Making |
0 |
0.02 |
| Tumor |
0 |
0.02 |
| Wound Management |
0 |
0.02 |